[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-406651-105":59,"doc-detail-406651-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sodium-glucose-cotransporter-2-inhibitors-beyond-glycemic-control-their-role-in-acute-kidney-injury-recovery-mini-review","Sodium-glucose cotransporter-2 inhibitors beyond glycemic control - Their role in acute kidney injury recovery - Mini-review","","With notable renal protective advantages beyond glycemic management, sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a cornerstone for type 2 diabetes mellitus and chronic kidney disease (CKD). While their role in CKD has been extensively explored, emerging evidence suggests protective effects in acute kidney injury (AKI), for which few pharmacologic options exist. This mini-review examines mechanisms including mitochondrial protection, oxidative stress attenuation, anti-inflammatory effects, reduced intraglomerular pressure, and modulation of tubuloglomerular feedback.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sodium-glucose-cotransporter-2-inhibitors-beyond-glycemic-control-their-role-in-acute-kidney-injury-recovery-mini-review/406651/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sodium-glucose-cotransporter-2-inhibitors-beyond-glycemic-control-their-role-in-acute-kidney-injury-recovery-mini-review/406651.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does this mini-review focus on?","Question",{"text":112,"@type":113},"It focuses on whether sodium-glucose cotransporter-2 (SGLT2) inhibitors can aid acute kidney injury (AKI) recovery, given the limited pharmacological options for AKI.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which mechanisms are proposed for SGLT2 inhibitors in AKI recovery?",{"text":117,"@type":113},"The review examines mitochondrial protection, oxidative stress reduction, anti-inflammatory effects, decreased intraglomerular pressure, and modulation of tubuloglomerular feedback.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence base is used, and what is the main limitation?",{"text":121,"@type":113},"The discussion relies on preclinical models and observational studies, while solid clinical trial data are limited, with robust randomized controlled trials still lacking.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},406651,1790688423,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","| W | J | N | World Journal of\u003Cbr>Nephrology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Nephrol 2025 December 25; 14(4): 112302  \nDOI: 10.5527/wjn.v14.i4.112302 ISSN 2220-6124 (online)  \nMINIREVIEWS  \nSodium-glucose cotransporter-2 inhibitors beyond glycemic control: Their role in acute kidney injury recovery  \nMuhammad Umar Ahsan, Sana Iftikhar, Umme E Ambreen, Fahad Nazir, Matia Fawad, Khadija Nasir, Ume Roman Leghari  \nSpecialty type: Urology and nephrology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B  \nNovelty: Grade B  \nCreativity or Innovation: Grade C  \nScientific Significance: Grade B  \nP-Reviewer: Guo R, Associate Professor, China  \nReceived: July 23, 2025  \nRevised: August 15, 2025  \nAccepted: December 8, 2025  \nPublished online: December 25, 2025  \nProcessing time: 153 Days and 17.9 Hours  \nMuhammad Umar Ahsan, Khadija Nasir, Ume Roman Leghari, Department of Medicine, D.G.Khan Medical College, Dera Ghazi Khan 32200, Punjab, Pakistan  \nSana Iftikhar, Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore 05450, Punjab, Pakistan  \nUmme E Ambreen, Fahad Nazir, Department of Medicine, CMH Institute of Medical Sciences, Bahawalpur 63100, Punjab, Pakistan  \nMatia Fawad, Department of Medicine, People’s University of Medical and Health Sciences for Women, Nawabshah 67450, Pakistan  \nCo-first authors: Muhammad Umar Ahsan and Sana Iftikhar.  \nCorresponding author: Muhammad Umar Ahsan, Researcher, Department of Medicine, D.G.Khan Medical College, College Chowk, Dera Ghazi Khan 32200, Punjab, Pakistan.  \n[umarahsan219@gmail.com](umarahsan219@gmail.com)  \nAbstract  \nWith notable Reno protective advantages beyond glycemic management, sodiumglucose cotransporter-2 (SGLT2) inhibitors have become a mainstay treatment for type 2 diabetes mellitus and chronic kidney disease (CKD) . Although SGLT2 inhibitors' involvement in the course of CKD has been well investigated, new research indicates that they may also have protective benefits in acute kidney injury (AKI), a condition for which there are few pharmacological treatments. The possible ways that SGLT2 inhibitors aid in AKI recovery are examined in this mini-review. These include mitochondrial protection, oxidative stress attenuation, anti-inflammatory effects, intraglomerular pressure decrease, and modulation of tubuloglomerular feedback. Although there is a lack of solid clinical trial data, preclinical models and observational studies suggest that SGLT2 inhibitors may lessen ischemia-reperfusion injury and contrast-induced nephropathy. This review addresses the possibility of incorporating SGLT2 inhibitors into AKI care regimens, critically evaluates the available data, and highlights important research gaps. Robust clinical trials are required to determine the safety, effectiveness, and ideal treatment window of SGLT2 inhibitors in this context, given the burden of AKI-related morbidity and mortality.  \n WJN  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 25, 2025  Volume 14  Issue 4   \nAhsan MU et al. SGLT2 inhibitors in AKI recovery  \nKey Words: Sodium-glucose cotransporter-2 inhibitors; Acute kidney injury; Renal protection; Ischemia-reperfusion; Oxidative stress; Tubuloglomerular feedback  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \nCore Tip: Sodium-glucose cotransporter-2 (SGLT2) inhibitors, traditionally used for glycemic control in type 2 diabetes, show emerging promise in acute kidney injury (AKI) recovery through mechanisms such as oxidative stress reduction, antiinflammatory effects, improved mitochondrial function, and hemodynamic modulation. Although encouraging data from preclinical and observational studies exist, robust randomized controlled trials are lacking. Th","cbCaijEKw8ql8Ffu","https://ap.wps.com/l/cbCaijEKw8ql8Ffu","pdf",3506479,"English","# Introduction\n## SGLT2 inhibitors beyond glycemic control\n## Burden and impact of acute kidney injury (AKI)\n## Rationale for exploring SGLT2 inhibitors in AKI recovery","[{\"question\":\"What problem does this mini-review focus on?\",\"answer\":\"It focuses on whether sodium-glucose cotransporter-2 (SGLT2) inhibitors can aid acute kidney injury (AKI) recovery, given the limited pharmacological options for AKI.\"},{\"question\":\"Which mechanisms are proposed for SGLT2 inhibitors in AKI recovery?\",\"answer\":\"The review examines mitochondrial protection, oxidative stress reduction, anti-inflammatory effects, decreased intraglomerular pressure, and modulation of tubuloglomerular feedback.\"},{\"question\":\"What evidence base is used, and what is the main limitation?\",\"answer\":\"The discussion relies on preclinical models and observational studies, while solid clinical trial data are limited, with robust randomized controlled trials still lacking.\"}]","Sodium-glucose cotransporter-2 inhibitors beyond glycemic control - Their role in acute kidney injury recovery - Mini-review | PDF",1790567008,18]